Lipocine Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2014; financial statements are unaudited. The filing was signed November 10, 2014.
Business context
Lipocine is a clinical-stage specialty pharmaceutical company developing oral drug-delivery products, principally for men’s and women’s health. Its lead candidate is LPCN 1021, an oral testosterone replacement therapy (TRT); LPCN 1111 is a next-generation oral TRT, and LPCN 1107 is an oral candidate for prevention of recurrent preterm birth. The company reported no product-sales revenue and remained dependent on equity financing and collaboration-related funding.
Financial results and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $3.25 million | $1.57 million | $12.59 million | $2.66 million |
| General and administrative expense | $0.87 million | $1.18 million | $3.83 million | $2.60 million |
| Net loss | $4.09 million | $3.48 million | $16.33 million | $6.20 million |
| Basic and diluted loss per share | $0.32 | $0.39 | $1.28 | $1.04 |
- Cash and cash equivalents were $31.67 million at September 30, 2014, down from $45.26 million at December 31, 2013. Current assets were $31.95 million and current liabilities $2.06 million.
- Cash used in operating activities was $13.61 million for the first nine months of 2014, versus $4.48 million in the comparable 2013 period. Investing cash use was negligible; financing provided $16,000, compared with $35.94 million in 2013, largely reflecting that year’s stock offering.
- Total liabilities were $2.06 million, consisting of current liabilities; the filing reports no debt or credit facility. The current ratio was approximately 15.5x. No meaningful operating margin is available because the company reported no product revenue.
- Accumulated deficit was $64.20 million. Management said existing resources were expected to fund projected operating requirements for the next 12 months, while also stating additional capital would be needed at some point. The company had no committed financing source.
Material changes versus comparable periods
- Nine-month R&D expense rose $9.93 million, primarily due to external clinical costs: $8.4 million related to LPCN 1021 and $1.5 million to other candidates. Contract research and development expense was $10.8 million for the nine months, versus $1.5 million in 2013.
- Nine-month net loss increased by $10.13 million, reflecting higher R&D and G&A costs. R&D expense in Q3 increased by $1.68 million, mainly due to LPCN 1021 Phase 3 clinical costs.
- Nine-month G&A expense increased $1.23 million, including higher compensation and stock-based compensation, public-company costs, and insurance and franchise-tax expenses. The 2013 comparison included $1.01 million of reverse-merger costs, which did not recur in 2014.
- Cash declined by $13.60 million over the first nine months of 2014. The comparable 2013 period included $36.0 million of common-stock offering proceeds.
Outlook, development updates, and risks
- LPCN 1021: The company reported that the SOAR Phase 3 trial met the primary efficacy guideline: 88% of the efficacy population, and 80% in a safety-set sensitivity analysis, achieved testosterone levels within the stated normal range. The safety extension remained ongoing. The company planned to file an NDA in the second half of 2015 if safety results were successful. It estimated $10.7 million to complete the planned process and expected LPCN 1021 R&D spending of $2–$3 million per quarter, subject to uncertainty.
- LPCN 1111: A Phase 2a study completed in October 2014 (after quarter-end) indicated feasibility of once-daily dosing and was reported as well tolerated, with no serious adverse events. The company expected to start a Phase 2b dose-finding study in Q1 2015.
- LPCN 1107: A second Phase 1 pharmacokinetic study in pregnant women was underway; results were expected in Q1 2015. The candidate remained early-stage, and the company noted that findings in healthy women might not predict results in pregnant women.
- Management expected operating losses and expenses to increase for several years as trials, manufacturing, regulatory preparation, research, and public-company activities continued. Additional financing may be required; unavailable or unfavorable financing could delay or reduce development programs.
- TRT regulatory and commercial risks were significant. Following a September 2014 FDA advisory committee meeting, most panelists supported revising the indicated population for TRT, and panelists also discussed cardiovascular-risk studies. FDA decisions, labeling restrictions, additional study requirements, safety findings, competition, and reimbursement could affect LPCN 1021 and LPCN 1111. A separate committee vote on another company’s oral TU product was adverse to that product’s benefit-risk profile; the filing noted this as a market and regulatory concern.
- Other commitments include approximately $1.0 million of remaining operating-lease payments through 2018. Potential Abbott royalties on future sales may apply if specified formulations or data are used: 1.5% or 1% of net sales, respectively, subject to stated terms. No royalties were incurred in the reported periods. Spriaso, a related party, held rights to cough-and-cold intellectual property under an agreement providing Lipocine up to $10 million in royalties; Spriaso extended the associated services agreement in July 2014.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of September 30, 2014.
Most important facts for investors to verify
- Completion and full safety results of the LPCN 1021 SOAR trial, and whether the timing and requirements for an NDA change.
- FDA decisions on TRT labeling, cardiovascular safety requirements, and whether additional studies or warnings are required.
- Actual spending and cash runway against the estimated $2–$3 million quarterly LPCN 1021 R&D pace, the $10.7 million completion estimate, and management’s financing assumptions.
- Clinical results and milestones for LPCN 1111 and LPCN 1107, including the pregnant-women study and planned Phase 2b initiation.
- Potential dilution or other financing terms, commercial reimbursement and competition, and any future Abbott royalties or Spriaso-related receipts.